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Abstract
Introduction: HIV worsens HCV-related liver disease by accelerating fibrosis progression; however, progression rates are
extremely variable among HIV/HCV-coinfected individuals. NK cells are associated with modulation of liver fibrosis and are
profoundly altered during HCV and HIV infections. CD4+ T-cells modulate NK cell function, and are also affected by HIV infec-
tion. Here, we aim to characterize the association of hepatic fibrosis with both the phenotype and function of peripheral NK
cells and their regulation by CD4+ T-cells, in HIV/HCV-coinfected individuals.
Methods: Thirty-four HIV/HCV-coinfected individuals with minimal (n = 16) and advanced (n = 18) fibrosis (METAVIR F0/F1
and F4 scores respectively) and 20 healthy volunteers were enrolled. PBMC were obtained from peripheral blood samples
and NK and CD4+ T-cells were isolated and analysed. NK cell phenotype (CD25, CD69, Nkp46, NKG2D, PD-1), degranulation
(CD107a) and IFN-c and TNF-a production, as well as CD4+ T-cell activation (CD69, CD25 and CD38) were measured by
flow cytometry. CD4+ T-cell conditioned medium (CM) derived from F0/F1 or F4 individuals was assessed for IL-2 levels by
ELISA. Modulation of NK cell functionality by these CMs was also analysed.
Results: When comparing to NK cells from individuals with minimal fibrosis, degranulation and cytokine secretion by NK cells
from subjects with F4 scores was significantly impaired, while PD-1 expression was augmented. On the one hand, neither the
expression of activation markers nor IL-2 secretion was distinctly induced in CD4+ T-cells from subjects with F0/F1 or F4
METAVIR scores. Finally, NK cell degranulation and cytokine secretion were not differentially modulated by CD4+ T-cell CM,
whether CD4+ T-cells derived from subjects with minimal or advanced fibrosis.
Conclusions: Low levels of NK and CD4+ T-cells in HIV/HCV-coinfected individuals with advanced liver fibrosis have been
previously described. Here, we show that advanced liver fibrosis in coinfected individuals is associated to a defective function
of NK cells and an increased expression of the exhaustion/senescence marker PD-1. This NK signature could not be attributed
to changes in the ability of CD4+ T-cells to modulate NK cell function.
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1 | INTRODUCTION
Nearly 71 million people worldwide are chronically infected
with the hepatitis C virus (HCV) [1]. Owing to overlapping
modes of transmission, coinfection with HCV and HIV is fre-
quent. Globally, 2.3 million individuals are estimated to be
coinfected with both viruses, with prevalence ranging between
10% and 90%, depending on populations and geographical
regions analysed [2]. Despite antiretroviral therapy (ART),
HIV-coinfected individuals present an accelerated course of
HCV-related liver disease compared to HCV-monoinfected
individuals [3,4]; immunosuppression and chronic inflammation
are some of the causes of such aggravation [5]. Additionally,
among HIV/HCV-coinfected individuals, some subjects pro-
gress to cirrhosis and others do not develop any degree of
liver fibrosis in their life time. Factors involved in such hetero-
geneity remain unidentified.
In humans, natural killer (NK) cells represent approximately
10% of peripheral blood mononuclear cells, but up to 30% to
50% of intrahepatic lymphoid cells [6]. As effectors of the
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innate immune system, NK cells target virally infected or trans-
formed cells by mediating cytotoxicity and producing proin-
flammatory cytokines. Additionally, cumulative evidence has
revealed that NK cells play an important role in inhibiting hep-
atic fibrosis [7]. Due to chronic hepatic injury, hepatic stellate
cells (HSCs) are activated, which leads to extracellular matrix
deposition, fibrosis and eventually, cirrhosis. Independent stud-
ies in both preclinical and clinical models have reported that
NK cells kill early activated or senescence-activated HSCs by
releasing cytotoxic granules or inducing death signals through
the expression of death receptors [8-14]. Secreted-IFN-c also
enhances antifibrotic effect of NK cells by inducing HSCs cycle
arrest and apoptosis [15]. Conversely, it has been suggested
that HSCs are capable of impairing NK cell antifibrotic capacity
[16,17].
Chronic HCV and HIV infections leave a distinct signature
on peripheral blood NK cells [18,19], and so, alterations of NK
cell phenotype and/or function were suggested as sensitive
biomarkers of viral exposure. To date, whether progression of
hepatic fibrosis in coinfected individuals is associated to a
defective NK function has not been demonstrated. In a previ-
ous study, we described that HIV/HCV-coinfected individuals
with advanced fibrosis presented lower percentages of CD4+
T-cells and NK cells compared with subjects with minimal
fibrosis [20]. Here, we show for the first time that progression
of liver fibrosis is associated to a defective NK cell function
that could not be attributed to a defective modulation by
CD4+ T-cells.
2 | METHODS
Healthy volunteers (HV, n = 20) and HIV/HCV-coinfected
individuals (n = 34) on follow-up at a Public Hospital Infec-
tious Diseases Unit, Buenos Aires, Argentina, were included in
this study. Written Informed Consent was obtained. Blood
samples were withdrawn at INBIRS Institute. The study was
conducted in accordance with the Declaration of Helsinki, and
was approved by the Bioethics Committee of Fundacion
Huesped. Sample collection and processing were performed
from July 2016 to July 2018.
HIV/HCV-coinfected individuals were classified based on
their level of fibrosis according to transient hepatic elastogra-
phy (FibroScan and SuperSonic Imagine’s Aixplorer). Sub-
jects with a result of ≤7.1 Kpa were classified as compatible
with a METAVIR score of F0/F1: absent or minimal fibrosis
and those with ≥12.5 Kpa as compatible with METAVIR F4:
cirrhosis [21-23]. Individuals enrolled in this study were not
acutely or chronically HBV-infected (determined by serology);
and denied current use of recreational drugs and more than
14 units/week of alcohol intake on a regular basis. HV were
recruited among hospital employees. To be included they had
to present a value of ≤5 Kpa on transient hepatic elastogra-
phy, had negative HIV/HCV/HBV serology, no history of alco-
hol, illicit drug consumption and other clinically relevant
conditions.
2.1 | Isolation of PBMC, NK and CD4+ T-cells
See Supporting Information.
2.2 | Activation of CD4+ T-cells
For CD4+ T-cell activation, 100,000 freshly isolated CD4+
T-cells were incubated with Dynabeads Human T-Activator
CD3/CD28 (Thermo Fisher, USA) at different bead-to-cell
ratios, for different times. Then, cells were processed by flow
cytometry to determine CD69, CD25 and CD38 expression.
Conditioned medium from activated CD4+ T-cells (CM) were
collected, and stored at 80°C.
For NK cytokine secretion assays, CM from CD4+ T-cells of
a selected HV was used. Selection of healthy CD4+ T-cells
was performed after certifying that activation was efficiently
induced by anti-CD3/CD28 beads (Figure S1A). To obtain
adequate amounts of material, supernatants from activated
(bead-to-cell ratio of 1:1, 48 hours) CD4+ T-cells of the
selected donor were obtained on two different occasions, and
subsequently pooled.
2.3 | Cytokine secretion
See Supporting Information.
2.4 | CD107a assay
For NK cell degranulation assays, the K562 cell line was used
as a sensible target at an effector to target ratio of 1:1.
PBMC were thawed and cultured overnight in cRPMI, at
37°C with 5% CO2. Next, one million viable PBMC were coin-
cubated for five hours with K562 cells, in the presence of
anti-CD107a-FITCmAb, brefeldin and monensin (4 lL, 10 lg/
mL and 0.7 lg/mL respectively, BD Biosciences, San Diego,
CA, USA). To assess the basal levels of degranulation, PBMC
were incubated in the absence of K562 cells.
Afterwards, we evaluated the effect of CM from CD4+
T-cells of HIV/HCV-coinfected individuals on healthy NK cells.
To avoid inter-subject bias, NK cells purified from a single HV
were used as effector. Selection of healthy NK cells was per-
formed after certifying that degranulation capacity was effi-
ciently induced by K562 cells (Figure S1B). Isolated NK cells
were pretreated for 18 hours with CM from activated CD4+
T-cells. Then, 100,000 viable NK cells were exposed to either
K562 cells or cRPMI, as formerly described.
2.5 | IFN-c and TNF-a secretion
For cytokine secretion assays, either PBMC or purified NK
cells were used. PBMC from HCV/HIV-coinfected individuals
were pretreated with either cRPMI or CM from activated
CD4+ T-cells from a selected HV. On the one hand, NK cells
from a single volunteer were pretreated with CM from HIV/
HCV-coinfected individuals. After 18 hours, cells were coincu-
bated with the K562 cell line, as described in the previous
section.
2.6 | Flow cytometric analysis
Cells were immunophenotyped by flow cytometry on a FACS
Canto Flow Cytometer (BD Biosciences). For antibodies and
gating strategies, see Table S1, Figure S2. Flow cytometry data
were analysed by FlowJo software v.10 (FlowJo Enterprise,
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Treestar Inc., Ashland, OR, USA). Phenotype and functionality
assays were performed according to cells availability.
2.7 | Statistical analysis
Statistical analyses were performed using GraphPad Prism
v.7.0 (GraphPad Software Inc., San Diego, CA, USA) and SPSS
software v.19.0 (SPSS Corp., Armonk, NY, USA). Parametric
and non-parametric tests were used as appropriate, for
details; see Supporting Information. Significance was assumed
at p < 0.05. (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001.
3 | RESULTS
3.1 | Frequency of NK and CD4+ T-cells is severely
diminished in HIV/HCV-coinfected individuals with
advanced fibrosis
This study enrolled HIV/HCV-coinfected individuals with mini-
mal or advanced fibrosis. All HIV-coinfected individuals were
on ART with undetectable HIV viral load, with no difference in
the time on ART between groups. One third of the individuals
in the advanced fibrosis group and 14% with minimal fibrosis
received IFN-based HCV treatment, with a median of eight
years (IQR eight to eleven years) before sampling, and none
of them achieve sustained virologic response. Age, time of
known HIV or HCV infection, and HCV genotypes were simi-
lar between individuals (Table 1). As expected, F4 group was
positively associated to liver stiffness, AST, c-GT, and total
bilirubin levels; and negatively to platelet count, albumin levels
and prothrombin time (Table 1). Male sex has been shown to
be positively related with liver fibrosis progression in HCV-
monoinfected or HIV/HCV-coinfected individuals [24,25].
Nevertheless, neither NK nor CD4+ T-cell frequencies were
associated with gender in our study.
In this new group of HIV/HCV-coinfected individuals, we
confirmed our previous observations [20] showing that
advanced fibrosis subjects displayed the lowest CD4+ T-cell
and NK cell frequencies (Table 2). Furthermore, we observed
that advanced fibrosis subjects displayed lower frequencies of
CD56dim but increased percentage of CD56bright cells than
HV, and individuals with minimal fibrosis.
3.2 | Functionality of NK cells is compromised in
individuals with advanced liver fibrosis
First, functionality of NK cells from HV, as well as HIV/HCV-
coinfected individuals was analysed. To evaluate NK cell
degranulation, we analysed the expression of cell surface
CD107a, as a measure of NK cell degranulation [26]. Interest-
ingly, basal (unstimulated) expression of CD107a differed
between groups, with the highest percentage of CD107a+ NK
cells corresponding to F4 individuals (Figure 1A, left panel).
However, after K562 coincubation, CD107a expression on NK
cells reached similar levels in HIV/HCV-coinfected individuals
and HV (Figure 1A, middle panel), suggesting an impaired abil-
ity of NK cells from F4 individuals to be activated ex vivo. In
fact, the degranulation response (fold change) induced upon
incubation of NK cells with K562 cells was significantly lower
in F4 individuals compared with the other two groups (Fig-
ure 1A, right panel). Interestingly, when F4 individuals were
analysed, the frequency of NK cells negatively correlated with
basal percentages of CD107a+ NK cells (Spearman rho
= 0.70, p = 0.0007), and positively, with the increased
degranulation response induced by K562 cells (Spearman
rho = 0.71, p = 0.0006) (Figure 1B).
Then, we analysed the pattern of cytokine secretion by NK
cells. In order to resemble physiologic activation of NK cells
by CD4+ T lymphocytes, cytokine secretion by NK cells from
both healthy and coinfected individuals was stimulated upon
pre-incubation with CM obtained from CD4+ T-cells activated
by anti-CD3/CD28 coated beads, as described in Figure 1C.
Control experiments performed with a HV showed that this
treatment effectively activated CD4+ T-cells, increasing the
expression of CD69 and the production of a number of
cytokines, and also that incubation of NK cells with the CM
obtained from activated CD4+ T-cells efficiently activated NK
cells, as indicated by the increased expression of CD107a
(Figure S1). We next analysed the production of IFN-c and
TNF-a by NK cells from all the enrolled groups after incuba-
tion with CMs obtained from activated CD4+ T-cells isolated
from a HV. In the absence of CM pretreatment, exposure to
K562 cells induced low levels of cytokine secretion. While
production of IFN-c did not differ among groups, TNF-a secre-
tion was greatly impaired in subjects with advanced fibrosis
(Figure 1D). In CM pretreated NK cells, the frequency of IFN-
c+ or TNF-a+ cells was significantly lower in F4 individuals
compared with healthy and F0/F1 individuals.
Due to small NK cell frequencies displayed by individuals
with advanced fibrosis, effector functions of CD56dim and
CD56bright populations could not be studied in all recruited
subjects. When analysing degranulation and both IFN-c and
TNF-a secretion on CD56dim population; we found similar
results as the obtained with total NK cells. Regarding
CD56bright cells, while CD107a expression was not signifi-
cantly affected (Figure S3A), there is a tendency towards a
reduction in cytokine production in METAVIR F4 subjects
(Figure S3B,C).
To further characterize NK cell populations in HIV/HCV-
coinfected subjects, the expression of the activation markers
CD25 and CD69, the activating receptors NKp46 and
NKG2D, and PD-1, a marker of cellular exhaustion, were
assessed on recently thawed PBMC (Figure 1E). While the
expression of PD-1 on NK cells was significantly higher in indi-
viduals with F4 scores, the other surface markers were not
differentially expressed in HIV/HCV-coinfected individuals.
Similar results were obtained analysing both the percentages
of NK cells expressing each marker (Figure 1E) and the med-
ian fluorescent intensity (MFI) for each of the markers anal-
ysed (not shown). Neither functional nor phenotypical
differences were found in NK cells according gender
(Table S2).
3.3 | Activation of CD4+ T-cells is similarly induced
in HIV/HCV-coinfected individuals with different
stages of hepatic fibrosis
Next, activation of CD4+ T-cells from HIV/HCV-coinfected
individuals was studied. Isolated CD4+ T-cells were stimulated
with anti-CD3/CD28 beads and frequencies of CD4+/CD69+,
CD4+/CD25+ and CD4+/CD38+ cells were measured. After
48 hours of stimulation at a bead-to-cell ratio of 1:1,
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frequency of CD4+/CD25+, CD4+/CD69+ and CD4+/CD38+
T-cells were increased in a similar way in both METAVIR F0/
F1 and F4 individuals (Figure 2A). Further experiments were
performed using a shorter incubation period and different
bead-to-cell ratios in order to reveal potential differences
between the two groups. No differences were observed
between HIV and HCV-coinfected individuals with minimal or
advanced liver fibrosis in terms of frequency of activated
CD4+ T-cells (Figure 2B). Similar results were obtained ana-
lysing MFI (not shown). Additionally, IL-2 levels in CD4+ T-cell
CM were evaluated by ELISA. In line with the previous
results, there were no significant differences between the
groups regarding IL-2 secretion at any tested condition (Fig-
ure 3A). Also, CD4+ T-cell activation did not vary between
Table 1. Subjects characteristics
Characteristics Control, n = 20 F0/F1, n = 16 F4, n = 18 p value
Age (years)a 44.4 (26 to 70) 47.1 (23 to 57) 51.2 (35 to 64) 0.20
Female sex (%)b 9 (45) 7 (44) 4 (22) 0.12
Prior IDU (%) - 11 (69) 15 (82) 0.42
CD4 count (cells/lL)a 1126.0 (629 to 2037)c 716.6 (153 to 1412) 563.8 (54 to 1278)c 0.002
CD8 count (cells/lL)a 722.4 (348 to 1566) 877.1 (321 to 1812) 947.8 (253 to 2230) 0.73
Known Time HCV infection (years)a - 16.0 (1 to 25) 16.3 (3 to 31) 0.67
Known time HIV infection (years)a - 19.9 (9 to 31) 19.3 (3 to 30) 0.80
Time of ART (years)a - 12.4 (7 to 17) 13.6 (8 to 20) 0.60
Previous use of ddI/d4T - 3 (20) 4 (25) >0.99
Present ART based on PI - 7 (46) 7 (38) >0.99
Present ART based on NNRTI - 5 (31) 2 (12) 0.21
Present ART based on INSTI - 4 (23) 9 (50) 0.17
Previous IFN/PEGIFN - 3 (14) 6 (33) 0.44
HCV genotype (%)a
Genotype 1a - 14 (87.5) 14 (77.7) 0.60
Genotype 1b - 2 (12.5) 1 (5.55)
Genotype 3a - - 2 (11.11)
Genotype 4 - - 1 (5.55)
HCV viral load (log10 copies)
a - 6.12 (3.14 to 7.54) 6.12 (4.74 to 7.38) 0.97
Liver stiffness (Kpa)a 4.50 (4 to 5) 6.02 (4 to 8)d 20.5 (12 to 36)d 0.008
APRI score nd 0.57 (0.25 to 1.34) 2.05 (0.42 to 11.6) 0.04
ALT (IU/L)a nd 64.3 (25 to 122) 90.9 (25 to 190) 0.09
AST (IU/L)a nd 50.6 (25 to 95) 94.1 (37 to 209) 0.007
c-GT (IU/L)a nd 118.9 (31 to 252) 185.9 (72 to 372) 0.06
Albumin (g/dL)a nd 4.33 (3.9 to 5.1) 4.07 (3.1 to 4.6) 0.09
Platelets (9103/mm3)a nd 200.0 (136 to 258) 141.2 (25 to 255) 0.003
Total bilirubin (lg/dL)a nd 0.59 (0.2 to 1.6) 1.30 (0.5 to 2.5) 0.0003
Prothrombin time (%)a nd 96.3 (84.8 to 100) 82.4 (50.9 to 100) 0.007
Time of known HIV/HCV infection is defined as the time from first HIV/HCV diagnosis by serology. ALT, alanine aminotransferase; ART, antiretro-
viral therapy; AST, aspartate transaminase; d4T, stavudine; ddI, didanosine; IDU, intravenous drug user; IFN/PEGIFN, interferon/pegilated inter-
feron; INSTI, integrase strand transfer inhibitor; nd, not determined; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease
inhibitors; c-GT, gamma-glutamyl transpeptidase.
aMean (range); bnumber of cases (number/total in %); cp=0.0005 control vs. F4; dp<0.0001 F0/F1 versus F4, ANOVA followed by Tukey0s test.
Table 2. Frequencies of peripheral blood lymphocyte populations in healthy volunteers and HIV/HCV-coinfected individuals
Characteristics Control F0/F1 F4 p value
CD4+ T-cells (%)a 43.07 (30.00 to 60.00) 32.80 (18.00 to 46.00) 23.53 (9.00 to 34.00) 0.033b, 0.0001c, 0.037d
NK cells (%)a 9.63 (4.03 to 17.35) 8.34 (3.13 to 14.40) 4.16 (1.29 to 10.11) 0.0004c, 0.003d
CD56 dim 96.56 (92.8 to 99.1) 97.46 (93.5 to 99.2) 87.95 (64.4 to 99.2) 0.01c, 0.007d
CD56 bright 3.44 (0.87 to 7.18) 2.54 (0.73 to 6.50) 12.05 (1.27 to 35.56) 0.01c, 0.007d
NK, natural killer.
aMean (range); bcontrol vs. F0/F1, ccontrol vs. F4, dF0/F1 versus F4.
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male and female subjects (Table S2). We conclude that there
are no differences in the activation pattern of CD4+ T-cells
obtained from individuals with minimal or advanced fibrosis.
3.4 | NK cell functionality is similarly modulated by
CD4+ T-cells purified from individuals with minimal or
advanced fibrosis
Finally, ex vivo stimulation of NK cells by cytokines from acti-
vated CD4+ T-cells of HIV/HCV-coinfected individuals was
evaluated. NK cells from a selected HV were pretreated with
CM from activated CD4+ T-cells (Figure 3B). Subsequently,
NK cells were coincubated with K562 cells, and CD107a
externalization, as well as cytokine production was measured.
As shown in Figure 3C, induction of NK cell degranulation
progressively decreased, as cells were pre-incubated with CM
from CD4+ T-cells stimulated with increasing cell-to-anti-CD3/
CD28 bead ratios, probably reflecting a decline in cytokine
concentration, for example, IL-2 (Figure 3A), in CD4+ T-cell
CM. However, no significant differences regarding CD107a
expression on healthy NK cells were registered after treat-
ment with CM from CD4+ T-cells of F0/F1 or F4 individuals,
at any tested condition. Cytokine secretion was similarly
upregulated regardless of the strength of CD4+ T-cell activa-
tion. In line with the previous degranulation results, fibrosis





























































































































































































































































































Figure 1. NK cell phenotype and functionality in HIV/HCV-coinfected individuals with minimal or advanced liver fibrosis.
(A) CD107a externalization in PBMC from control and HIV/HCV-coinfected individuals with METAVIR F0/F1 or F4 scores incubated with cRPMI
(basal) or K562 cells (+K562). (B) Correlation between frequency of NK cells and degranulation capacity in F4 individuals. (C and D) For IFN-c
and TNF-a expression, NK cells were pretreated with conditioned medium (CM) from CD4+ T lymphocytes or cRPMI, and subsequently exposed
to K562 cells. (E) PBMCs were stained for CD25, CD69, NKp46, NKG2D and PD-1 markers. Individual NK cell frequencies, median and 25th
and 75th percentiles are indicated. Statistical comparisons were performed using Kruskal-Wallis followed by Dunn0s multiple-comparison tests
(A and D) and Mann-Whitney test (E). NK, natural killer.
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IFN-c or TNF-a production by NK cells. MFI evaluation of
degranulation and cytokine secretion yielded similar results
(not shown).
In summary, we did not observe differences in the capacity
of CD4+ T-cells from individuals with minimal or advanced
fibrosis, to modulate neither NK cell degranulation or IFN-c
and TNF-a secretion.
4 | DISCUSSION
Progression of liver disease in HCV-monoinfected and HIV/
HCV-coinfected individuals is extremely variable. In our
patient cohort, HIV/HCV-coinfected individuals had similar
time of known HIV and HCV infection and ART, however,
some of them progressed to cirrhosis whereas others had
minimal liver fibrosis. NK cells have shown to play an impor-
tant role in the immune response against HCV infection and
in the modulation of liver fibrosis development. It was previ-
ously reported in HCV monoinfection and HIV/HCV coinfec-
tion that peripheral NK cell frequency is significantly
decreased [27-29]. Recently, we showed that among HIV/
HCV-coinfected subjects, advanced fibrosis was associated to
the lowest frequencies of circulating NK cells [20]. Although it
has been suggested that NK cells were preferentially localized
in liver tissue during viral chronic infections [30], mechanisms
for decreased peripheral NK cell frequencies in individuals
with advanced fibrosis are not fully understood. In the present
study, we report that the compartment of NK cells in patients
with advanced fibrosis shows not only a quantitative defect
but also a compromise in cell functionality.
In this study, we show that ex vivo degranulation of NK
cells from cirrhotic individuals coinfected with HIV and HCV
is poorly induced by K562 cells, perhaps reflecting an
exhausted phenotype. Augmented levels of basal degranula-
tion were described in antiretroviral-treated HIV-positive
individuals [31], possibly indicating the presence of targets
for NK cell-mediated natural cytotoxicity in the course of
infection. HCV-associated immune response, and also both
hepatic and systemic proinflammatory milieu may contribute
to this phenomenon. Interestingly, here we show that cir-
rhotic patients with the lowest NK cell frequencies displayed
the greatest percentages of basal CD107a+ NK cells, and
the weakest induction of NK cell degranulation by K562
cells. This observation indicates that the frequency and func-
tion of NK cells could be related, although the mechanisms
underlying this association remain to be defined. Our results
suggest that in HIV/HCV-coinfected individuals, liver damage
may lead to in vivo over-activation and functional exhaustion
(i.e. the impossibility to exhibit a significant degranulation
upon exposure to susceptible targets) of peripheral NK cell
subset.
Regarding cytokine secretion, we show that IFN-c and TNF-
a production by NK cells is significantly impaired in individuals
with advanced fibrosis. In particular, our results may indicate
that NK cells from F4 individuals failed at responding to
CD4+ T-cell derived stimuli. Nevertheless, since NK cells were
studied in PBMC fractions, interaction with other immune
cells and their products may have influenced the observed
results. It is evident that experimental settings, for example,
cytokine prestimulation of NK cells, evaluation of spontaneous
degranulation, and interaction with other immune cells are
critical when analysing ex vivo NK cell cytotoxicity. Together,
our results are consistent with those reporting impaired func-
tionality of NK cells during HCV monoinfection [32-36], and
also HIV/HCV coinfection [29]. However, they could be also
interpreted in the context of a functional NK cell dichotomy,
where NK cells display a decreased production of antiviral
cytokines but an enhanced basal cytotoxicity, which is impaired
when these cells are exposed to their targets [18,37]. Cyto-
kine secretion and cytotoxicity can be uncoupled when NK





































































































































Figure 2. Activation of CD4+ T-cells from HIV/HCV-coinfected individuals with minimal or advanced liver fibrosis.
(A) CD69, CD25 and CD38 expression were measured on CD4+ T-cells from HIV/HCV-coinfected subjects with METAVIR F0/F1 or F4 scores
after 48 hours of vehicle (basal) or anti-CD3/CD28 stimulation (bead-to-cell ratio of 1:1). (B) The same markers were determined after anti-CD3/
CD28 stimulation (1:5 or 1:35 ratios; 24 hours). Individual CD4+ T-cell frequencies, median and 25th and 75th percentiles are indicated. Statisti-
cal comparisons were performed using Wilcoxon matched paired test (A) and Mann-Whitney test (B).
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Possible mechanisms underlying a compromised NK cell
function in the course of HCV infection have been related to
changes in the activation state and/or an imbalanced NK cell
receptor expression [39]. Here, we evaluated CD69, CD25,
NKp46 and NKp30 cell markers but only PD-1 expression
was associated to liver fibrosis progression. In line with the
results from functional assays, PD-1 expression may be
reflecting an exhausted NK pool in individuals with advanced
liver fibrosis. Although PD-1 expression in NK cells was
already linked to chronic HCV infection [40], to the best of
our knowledge, no relationship between advanced liver fibro-
sis and the PD-1/PDL-1 axis in NK cells has been previously
addressed. Further studies are required to analyse the utility
of PD-1 as a marker of fibrosis progression as well as to
explore whether PD-1 could represent a potential immune
check point for targeted therapies aimed to modulate liver
fibrosis.
Despite all individuals were on successful ART therapy, F4
individuals have lower CD4+ T-cell counts and percentages
than subjects with minimal fibrosis. Studies of liver fibrosis
progression in HIV seronegative individuals have proposed
that low absolute CD4+ T-cell counts may be attributable to
advanced liver disease, due to hypersplenism secondary to
portal hypertension, and consequently, leucopenia [41-43].
Nevertheless, hypersplenism could not be associated with the
decrease in the percentage CD4+ T-cell observed in our group
of cirrhotic individuals (since leucopenia affects the absolute
number of the different leucocytes but not the proportion of
them). Therefore, our results suggest that the lower frequency
of these cells could be associated with the progression to liver
fibrosis rather than being a consequence of end stage liver
disease. It is well known that CD4+ T-cells boost NK cell acti-
vation via IL-2 secretion [44] and recently, impaired CD4+ T-
cell stimulation of NK cells has been linked to liver fibrosis by
comparing HV and HIV/HCV-coinfected individuals, [45]. Our
present observations differ from this study in two ways. First,
we did not analyse coinfected subjects as a unique population,
but rather we stratified coinfected individuals according to
their degree of fibrosis, enabling us to define associations
between the degree of fibrosis and the phenotype and func-
tion of NK cells. Second, we observed that the response to
activation stimuli of CD4+ T-cells in coinfected subjects as
well as their ability to modulate the function of NK cells did
not differ between individuals with minimal and maximal
degree of fibrosis. It has been reported that HIV/HCV-coin-
fected subjects with higher chances to develop liver fibrosis
are those with lower CD4+ T-cell recovery after HIV treat-
ment [46]. In view of our results, CD4+ T-cell count might
contribute more significantly to fibrosis progression than a
deficient CD4+ T-cell modulation capacity.
Our study has some limitations. First, a larger sample size
would permit stronger associations between variables, and
especially to robustly address NK CD56bright population. Also,
it would be very interesting to study CD56neg NK cells, since
they are described as an aberrant and hypo functional cell
subset found at elevated levels in individuals chronically
infected with HIV-1 and HCV [47]. Finally, although the main
focus of our study was to determine whether CD4+ T-cells
from coinfected individuals with minimal or advanced fibrosis
had different capacity to stimulate NK cells, we cannot rule
out that a defect in the function of HIV- or HCV-specific
CD4+ T-cells might contribute to NK cell dysfunction in coin-
fected subjects. It would be very interesting to investigate the
potential role of HIV- or HCV-specific CD4+ T-cells to modu-
late liver fibrosis.
5 | CONCLUSIONS
Association between NK cell phenotype and function and the
outcome of acute HCV infection was extensively reported
[48-50], nevertheless, it remains unclear whether phenotypical
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Figure 3. Ex vivo effect of CD4+ T-cells from HIV/HCV-coinfected individuals with minimal or advanced liver fibrosis on NK cells.
(A) IL-2 levels in CM. (B) Conditioned medium (CM) from activated CD4+ T-cells from HIV/HCV-coinfected subjects with METAVIR F0/F1 or F4
scores were collected, and subsequently used for pretreatment of NK cells from one healthy individual. Finally, NK cells were coincubated with
K562 cells. (C) CD107a, IFN-c and TNF-a expression on NK cells. Individual CD4+ T-cell frequencies, median and 25th and 75th percentiles are
indicated. Statistical comparisons were performed using Mann-Whitney test. NK, natural killer.
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and/or functional characteristics of NK cells are actually deter-
minants for the rate of liver fibrosis progression. We and
others have previously shown an association between low NK
and CD4+ T-cell counts with advanced liver fibrosis in HIV/
HCV-coinfected individuals [20,29]. Here, we provide further
support for this phenomenon, and also demonstrate that NK
functionality is significantly impaired in coinfected individuals
with advanced fibrosis. Although the underlying mechanisms
remain to be defined, our results suggest they could not be
attributed to an inefficient modulation of NK cell function by
CD4+ T-cells. In sum, lower CD4+ T and NK cells, as well as a
decreased NK functionality may represent ex vivo biological
markers of advanced liver disease.
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Figure S1. Lymphocytes isolated from a selected healthy vol-
unteer. NK and CD4+ T-cells were purified from PBMC of a
42-year-old woman, HIV/HCV/HBV negative, with no history
of alcohol consumption, tabaquism or ilicit drug use, thyroid or
celiac disease, and no other clinically relevant conditions. %
NK cells: 8.62, CD4+ T-cell count: 754, % CD4+ T-cells: 38.
(A) CD4+ T-cells were stimulated with anti-CD3/CD28 beads
in different bead-to-cell ratios (1:1, 48 hours; others
24 hours), and percentages of CD69+/CD4+ T cells were
monitored. IL-2 levels were also measured in corresponding
culture supernatants. Right: Additional cytokines were quanti-
fied in CD4+ T-cell CM (1:1, 48 hours). (B) CD107a external-
ization in CM-prestimulated PBMC, co-cultured with K562
cells (CM+K562). As control, cRPMI-prestimulated PBMC
were either exposed to K562 cells (+K562) or cRPMI (basal).
Determinations were performed in duplicate. Data are pre-
sented as mean  SD. Statistical comparisons were performed
using Wilcoxon matched paired test. nd, not detected.
Figure S2. Gating strategy, and representative dot plots for
flow cytometry analysis. (A) NK cell subset was defined as
CD3-/CD56+ viable lymphocytes. (B) Upon incubation with
cRPMI (basal) or K562 cells (+K562), CD107a+ NK cells were
determined (Top). Intracellular IFN-c and TNF-a expression
was measured in cRPMI or CM-prestimulated NK cells, co-cul-
tured with K562 cells (Bottom). (C) CD69+, CD25+ or
CD38+ cells were determined in vehicle (control) or anti-
CD3/CD28-stimulated CD4+ T-cells. At least one thousand
events were acquired for both NK and CD4+ T-cell gates.
Figure S3. Evaluation of NK cell effector functions in CD56
dim and bright populations. (A) PBMCs from healthy and HIV/
HCV-coinfected individuals with METAVIR F0/F1 or F4 scores
were incubated with cRPMI (basal) or K562 cells (+K562).
Fold change induction in CD107a expression (+K562/basal)
was evaluated in CD56dim and CD56bright cell subsets. (B and
C) For cytokine expression, PBMCs cells were pretreated with
conditioned medium from CD4+ T-lymphocytes, and subse-
quently exposed to K562 cells. Frequencies of IFN-c (B) and
TNF-a-positive cells (C) were determined in CD56dim and
CD56bright cell subsets. Statistical analysis was performed
using Kruskal-Wallis followed by Dunn0s multiple-comparison.
Table S1. Fluorochrome-conjugated antibody panels.
Table S2. Differences in NK and CD4+ T-cell phenotypic and
functional markers according gender.
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